Varian Creates Patient Education Web Site

Publication
Article
OncologyONCOLOGY Vol 13 No 1
Volume 13
Issue 1

Varian has created a new patient education Internet web site containing information on cancer radiotherapy treatments.

Varian has created a new patient education Internet web site containing information on cancer radiotherapy treatments. The site includes information from the National Cancer Institute and leading cancer treatment centers. Varian’s cancer patient education web site is located at www.varian.com/hcs /rad.

Articles in this issue
Varian Creates Patient Education Web Site
M. D. Anderson Researchers to Study Quality of Life in Testicular Cancer Patients
Follow-up Essential for Positive Home HIV Test Results
FDA Treads Delicate Line Between Safety and Speed
Estrogen May Reduce Colorectal Cancer Risk in Postmenopausal Women
Surgeons Issue Consensus Statement on Performing Sentinel Lymph Node Biopsy
Sentinel Lymph Node Mapping in Breast Cancer
Komen Foundation Receives Grant to Develop New Breast Imaging Technology
New Imaging Agent Seems to Enhance Detection of Metastatic Breast Cancer
NCI to Sponsor Phase III Trials of Liquid Shark Cartilage Angiogenesis Inhibitor
Aspirin Decreases Genetic Mutations Associated With Inherited Colon Cancer
Open Lung Biopsy Cost-Effective in Evaluating Solitary Pulmonary Nodules
Sentinel Lymph Node Mapping in Breast Cancer
Chemoprevention of Colorectal Cancer: Dietary and Pharmacologic Approaches
Clinical Status and Optimal Use of Amifostine

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content
Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Ibrilatazar Shows Survival Improvement in Advanced Squamous NSCLC

Roman Fabbricatore
June 6th 2025
Article

Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging

Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

Tim Cortese
June 6th 2025
Article

A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Gina Mauro
June 5th 2025
Article

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

Ashling Wahner
June 5th 2025
Article

Frontline BNT327/PM8002 plus chemotherapy led to a confirmed ORR of 51.6% and a DCR of 90.3% in patients with unresectable pleural and peritoneal mesothelioma.